The beneficial consequences of increased expression and activity of these transporters relate to cancer-cell survival and proliferation in multiple ways: acquisition of essential amino acids (SLC7A5 and SLC6A14), glutamine (SLC7A5, SLC1A5, SLC6A14 and SLC38A5), methionine (SLC7A5, SLC6A14 and SLC38A5), serine (SLC1A5, SLC7A5, SLC6A14, SLC38A5, and SLC43A2), and cystine (SLC7A11). The gene discussed is SLC7A5; the disease is cancer.